MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadershipLynne Murray, Ph.D., MBA appointed as Chief Scientific...

Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointmentsMiroBio is exclusively focused on checkpoint agonists...